Rheumatoid Arthritis

New data show rheumatoid arthritis and immunosuppressive treatment associated with more severe risks of COVID-19, including hospitalization and death.

A study characterizing frailty in patients with rheumatoid arthritis finds psychosocial factors could be more important determinants than aging.

Mortality rates were similar in COVID-19 patients with and without chronic inflammatory diseases.

The difficult-to-treat disease has a multitude of symptoms to address with a wide spectrum of agents.

A meta-analysis notes that relative risk for stroke was high for rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, and gout.

Investigators compared a self-directed, stepped exercise program to improve symptoms of knee osteoarthritis in randomized trial to an education-based approach.

The IL-23 inhibitor is shown to improve disease activity across joint and skin symptoms.

Long-term outcomes in systemic lupus erythematosus have improved over time, but unmet needs include glucorticoid dependency and comorbidity burden.

Patients with the rare skin disorder are at a notably heightened risk for developing arthritis, according to a large-scale cohort study

Patients with SLE or RA had comparable mean QTc length, regardless of whether or not they received hydroxychloroquine treatment

The monoclonal antibody has built on its 18-month portfolio with sustained renal benefits for the at-need patient group.

A new study contributes to the growing discussion around rheumatic disease treatment disparities.

Just 2% of observed older men to experience an indicative fracture received a diagnosis and treatment for osteoporosis over a four-year period.

New survey findings show the antimalarial drug's promotion for potential SARS-CoV-2 benefit early into the pandemic led to needing patients losing access.

An interview with a study author on implementing artificial intelligence into rheumatic care.

Data suggest patients administered tofacitinib for their arthritis do not face worsened risk, severity of flu infection.

The first 3 months of the pandemic were marked by a significant rate of patients changing or discontinuing medication without clinician guidance.

New data show patients with arthritis and psoriasis are far more likely to quarantine and isolate than similar patients, differentiating by treatment type.

New data from ACR 2020 assure concerns that patients with arthritis who test positive for COVID-19 may be at worse risk of ICU admission or even death.

Risk of herpes zoster and creatine phosphokinase increased with use of upadacitinib.

This approval makes the drug the first of its kind to treat polyarticular juvenile idiopathic arthritis and psoriatic arthritis in a pediatric population.

Findings indicate placebo responses are more than a psychological placebo effect.

Rheumatologists and OB-GYNs must communicate openly with each other and to patients with rheumatic diseases who are considering pregnancy.